Arbor Biotechnologies Announces FDA Acceptance of IND Application for ABO-101 for the Treatment of Primary Hyperoxaluria Type 1
19 déc. 2024 07h00 HE
|
Arbor Biotechnologies Inc
CAMBRIDGE, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Arbor Biotechnologies™, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that the U.S....
Arbor Biotechnologies to Highlight New Preclinical Data Supporting Advancement of Pipeline Programs and Knock-In Applicability of Type V Nucleases at Upcoming Medical and Scientific Meetings
22 oct. 2024 16h17 HE
|
Arbor Biotechnologies Inc
Oral presentation at ASN on lead program, ABO-101 for primary hyperoxaluria type 1 (PH1), supporting in vivo proof of pharmacology. On-track for year-end IND/CTA filing.Oral presentation at ALS One...
Arbor Biotechnologies Presents Data Supporting Clinical Development of ABO-101 and Robust Potential of Platform to Enable Therapeutic Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
09 mai 2024 06h00 HE
|
Arbor Biotechnologies Inc
Presented data which, along with ongoing IND-enabling studies, demonstrate efficacy and pharmacology of ABO-101 in non-human primates (NHPs), supporting continued development as a potential novel gene...
Arbor Biotechnologies Announces Acquisition of Serendipity
08 mai 2024 07h00 HE
|
Arbor Biotechnologies Inc
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced the...
Arbor Biotechnologies to Present Data Supporting Therapeutic Programs in PH1 and ALS, and the Discovery of a Novel Type V Nuclease at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
22 avr. 2024 17h09 HE
|
Arbor Biotechnologies Inc
- Oral and poster presentations showcase data demonstrating pipeline progress and continued advancement of Arbor’s pipeline programs toward the clinic - Oral presentation with data validating...
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
03 janv. 2024 08h01 HE
|
Arbor Biotechnologies Inc
Partnership brings together two leaders in next-generation genetic medicines to engineer, co-develop and co-commercialize (50:50 profit share) AAV-delivered CRISPR/Cas-based therapeutics for up to six...
Arbor Biotechnologies Appoints Industry Veteran R. Nolan Townsend to Board of Directors
07 nov. 2023 07h00 HE
|
Arbor Biotechnologies Inc
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the...
Arbor Biotechnologies Appoints Ajim Tamboli as Chief Financial Officer
29 août 2023 07h00 HE
|
Arbor Biotechnologies Inc
CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the...
Arbor Biotechnologies Appoints Deanna M. Petersen as Chief Business Officer
07 août 2023 07h00 HE
|
Arbor Biotechnologies Inc
CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the...
Arbor Biotechnologies to Present at the Stifel 2023 Tailoring Genes: Genetic Medicines Day
23 mai 2023 07h00 HE
|
Arbor Biotechnologies Inc
CAMBRIDGE, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced Devyn Smith,...